BOSTON--(BUSINESS WIRE)--Elucid has announced that four of the seven Medicare Administrative Contractors (MACs) will extend coverage for AI-enabled quantitative coronary plaque analysis, including its FDA-cleared PlaqueIQTM image analysis software, beginning November 24, 2024. The updated policy will allow for Medicare patients whose claims are administered within the four MACs who present with acute or stable chest pain and no known history of cardiovascular disease to be assessed with AI-enabled plaque imaging software that can help physicians accurately diagnose and potentially personalize treatment for cardiovascular disease..

波士顿--（商业新闻短讯）--Elucid宣布，从2024年11月24日开始，七家医疗保险管理承包商（MACs）中的四家将扩大人工智能定量冠状动脉斑块分析的覆盖范围，包括其FDA批准的PlaqueIQTM图像分析软件。更新后的政策将允许在四个MACs中进行索赔的医疗保险患者，这些患者表现为急性或稳定的胸痛，并且没有已知的心血管疾病史，可以使用人工智能斑块成像软件进行评估，该软件可以帮助医生准确诊断并可能个性化治疗心血管疾病。。

“In the United States, one person dies every 33 seconds from cardiovascular disease.i The most common cause of death and disability, CAD is largely driven by myocardial infarction and ischemic stroke caused by atherosclerosis,' said Nehal Mehta, MD MSCE, cardiologist and Professor of Medicine at George Washington University School of Medicine.

乔治华盛顿大学医学院心脏病专家、医学博士内哈尔·梅塔（NehalMehta）说：“在美国，每33秒就有一人死于心血管疾病。我是最常见的死亡和残疾原因，冠心病主要是由动脉粥样硬化引起的心肌梗塞和缺血性中风引起的。”。

'The decision by four of the seven Medicare Administrative Contractors to extend coverage for Elucid's PlaqueIQ image analysis software expands its value as a tool to help physicians identify coronary artery disease - and the plaque that can lead to it - in a non-invasive manner. The sooner these plaques are detected, the sooner effective therapies to prevent plaque rupture can be started.'.

“七家医疗保险管理承包商中有四家决定扩大Elucid PlaqueIQ图像分析软件的覆盖范围，这扩大了其作为帮助医生以非侵入性方式识别冠状动脉疾病（以及可能导致冠状动脉疾病的斑块）的工具的价值。这些斑块越早被检测到，预防斑块破裂的有效疗法就可以越早开始。”。

Elucid’s PlaqueIQ is the first FDA-cleared non-invasive software that can objectively quantify and classify plaque morphology based on ground-truth histology, the gold standard for characterization of plaques. PlaqueIQ is designed to give physicians new, clinically validated information to help stratify patients and inform patient-specific treatment pathways..

Elucid的PlaqueIQ是第一个FDA批准的非侵入性软件，可以根据地面真实组织学（斑块表征的金标准）客观地量化和分类斑块形态。PlaqueIQ旨在为医生提供新的，经过临床验证的信息，以帮助对患者进行分层，并告知患者特定的治疗途径。。

“Elucid commends the MACs’ recognition of the importance of innovation in quantifying and classifying coronary artery plaque, which is the strongest predictor of heart attack and stroke in patients,” said Kelly Huang, CEO of Elucid. “The agency’s extended coverage will allow us to provide physicians and patients greater access to ground-truth histology-based technology that offers new insights into plaque to help aid diagnosis, influence treatment decisions, and reduce the devastating impact of cardiovascular disease.

Elucid首席执行官黄凯利（KellyHuang）表示：“Elucid赞扬MACs认识到创新在量化和分类冠状动脉斑块方面的重要性，冠状动脉斑块是患者心脏病发作和中风的最强预测指标。”。“该机构的扩大覆盖范围将使我们能够为医生和患者提供更多的基于组织学的地面真相技术，该技术为斑块提供新的见解，以帮助诊断，影响治疗决策，并减少心血管疾病的破坏性影响。

We are thankful to our partners who include physicians, medical societies, and industry colleagues for their support of our input into improving access to AI plaque quantification for patients who can benefit the most.”.

我们感谢包括医生，医学会和行业同事在内的合作伙伴，感谢他们支持我们的投入，以改善能够最大程度受益的患者获得AI斑块定量的机会。”。

PlaqueIQ utilizes first-line diagnostic CCTA and develops comprehensive, interactive reports to help physicians virtually “see” and quantify plaque. With its basis in histology, the software is uniquely able to non-invasively quantify and characterize plaque and its components such as lipid-rich necrotic core (LRNC), giving potential insights into high-risk plaques that are key drivers of risk of heart attack and stroke.

PlaqueIQ利用一线诊断CCTA并开发全面的交互式报告，以帮助医生实际上“看到”和量化斑块。凭借其组织学基础，该软件独特地能够无创地量化和表征斑块及其成分，如富含脂质的坏死核心（LRNC），从而为高风险斑块提供潜在的见解，这些斑块是心脏病发作和中风风险的关键驱动因素。

In addition, use of the software has the potential to enable earlier identification of higher-risk plaque before presence of symptoms or major adverse events..

此外，使用该软件有可能在出现症状或重大不良事件之前尽早识别出高风险斑块。。

About Elucid

关于Elucid

Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company’s PlaqueIQTM product is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease.

Elucid是一家总部位于波士顿的人工智能医疗技术公司，致力于开发技术，旨在为医生提供更精确的动脉粥样硬化（冠状动脉斑块积聚）视图，动脉粥样硬化是心血管疾病的根本原因。该公司的PlaqueIQTM产品旨在帮助医生根据实际疾病而不是基于人群的疾病风险来优先考虑和个性化治疗。

PlaqueIQ is the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke.

PlaqueIQ是唯一一种FDA批准的计算机断层扫描血管造影（CTA）算法，它可以客观地量化斑块形态，并根据著名病理学家指出的斑块表征的金标准ground truth组织学进行验证。PlaqueIQ为医生提供了有关可能导致心脏病发作和中风的动脉斑块类型和数量的关键信息。

Elucid is also pursuing an indication for FFRCT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit elucid.com..

Elucid也在寻求FFRCT的适应症，该适应症源自其斑块算法，以帮助无创地识别冠状动脉阻塞和缺血程度。有关更多信息，请访问elucid.com。。

i National Center for Health Statistics. Multiple Cause of Death 2018–2022 on CDC WONDER Database. Accessed May 3, 2024. https://wonder.cdc.gov/mcd.html

国家卫生统计中心。CDC WONDER数据库上的2018-2022年多死因。2024年5月3日访问。https://wonder.cdc.gov/mcd.html